Respiratory Research Analysis
Across May, respiratory research converged on translational targets and platforms spanning airway biology, antiviral prevention, and organ preservation. The strongest signals include an epithelial lipid–ER–mitochondrial axis (CEPT1) driving asthma, IL‑33/ST2 blockade (astegolimab) reducing COPD exacerbations irrespective of eosinophils, and oral postexposure prophylaxis with ensitrelvir that significantly prevents symptomatic COVID‑19 in household contacts. NK‑cell checkpoint biology (HLA‑E–NKG2
Summary
Across May, respiratory research converged on translational targets and platforms spanning airway biology, antiviral prevention, and organ preservation. The strongest signals include an epithelial lipid–ER–mitochondrial axis (CEPT1) driving asthma, IL‑33/ST2 blockade (astegolimab) reducing COPD exacerbations irrespective of eosinophils, and oral postexposure prophylaxis with ensitrelvir that significantly prevents symptomatic COVID‑19 in household contacts. NK‑cell checkpoint biology (HLA‑E–NKG2A) emerged as a druggable antifibrotic pathway, while human‑relevant lung‑on‑chip mechanobiology enabled causal links between airway compression and remodeling. Together, these advances point to near‑term shifts in biologic indications, precision respiratory therapeutics, and scalable prevention strategies.
Selected Articles
1. FOXA1-mediated CEPT1 deficiency in airway epithelium drives asthma via an ER stress-mitochondrial dysfunction axis.
Mechanistic work shows CEPT1 downregulation in asthmatic airway epithelium induces phospholipid imbalance, activates all three ER stress branches, disrupts ER Ca2+ homeostasis, and triggers mitochondrial dysfunction; a FOXA1–CEPT1 regulatory axis links epithelial lipid metabolism to stress responses and inflammation.
Impact: Reveals a targetable epithelial lipid–ER–mitochondrial mechanism for asthma, nominating CEPT1 as a therapeutic and biomarker candidate for precision interventions.
Clinical Implications: Supports therapies to restore phosphatidylcholine balance, upregulate CEPT1, or mitigate ER/mitochondrial injury; CEPT1 expression could stratify patients for targeted trials.
Key Findings
- CEPT1 is significantly downregulated in asthmatic airway epithelium.
- CEPT1 deficiency induces phospholipid imbalance, activates all three ER stress branches, and disrupts ER Ca2+ homeostasis.
- Mitochondrial dysfunction mechanistically links epithelial metabolic defects to asthma pathophysiology; FOXA1 regulates CEPT1.
2. Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials.
Two large randomized, double-blind, placebo-controlled trials showed astegolimab (anti‑ST2) reduced annualized moderate/severe COPD exacerbations versus placebo with acceptable safety, with efficacy observed across eosinophil strata.
Impact: Among the first eosinophil-agnostic biologic programs demonstrating exacerbation reduction in COPD, potentially expanding therapeutic options in a high-need population.
Clinical Implications: If approved, astegolimab may be integrated as add-on therapy for frequent-exacerbator COPD regardless of eosinophils, informing exacerbation-reduction pathways and biomarker refinement.
Key Findings
- Astegolimab reduced annualized moderate/severe exacerbations vs placebo in two pivotal trials.
- Efficacy signals were observed across eosinophil strata.
- Safety and mortality were balanced across groups.
3. Astrocyte activation in the ventrolateral medulla modulates breathing and arousal states.
In alert mice, Aldh1l1-positive astrocytes in the ventral respiratory column activate prior to sighs and are recruited by hypoxia; opto/chemogenetic activation increases sigh-linked arousals and enhances calcium transients in nearby catecholaminergic neurons.
Impact: Defines a causal astrocyte–neuronal circuit for hypoxia-evoked ventilatory and arousal responses, informing disorders of breathing control and arousal.
Clinical Implications: Suggests circuit- or pharmacology-based avenues to modulate arousal and ventilatory responses in sleep-disordered breathing, neonatal hypoxia vulnerability, or impaired arousal syndromes.
Key Findings
- A subset of ventral respiratory column astrocytes activates before sighs and is recruited by hypoxia.
- Opto/chemogenetic activation increases sigh-linked arousals.
- Astrocyte activation augments calcium transients in nearby catecholaminergic neurons immediately before arousal-with-sigh events.
4. Ensitrelvir for Covid-19 Postexposure Prophylaxis in Household Contacts.
In a double-blind randomized trial of 2,041 household contacts, a 5-day oral ensitrelvir regimen started within 72 hours reduced symptomatic PCR-confirmed COVID-19 by day 10 (2.9% vs 9.0%; RR 0.33) with an adverse-event profile comparable to placebo.
Impact: Provides definitive RCT evidence for oral postexposure prophylaxis against SARS‑CoV‑2 in households with favorable safety, directly informing outbreak and household management.
Clinical Implications: Supports guideline consideration of ensitrelvir PEP within 72 hours for eligible household contacts, with ongoing monitoring across variants and vaccination strata.
Key Findings
- Primary outcome by day 10: 2.9% (ensitrelvir) vs 9.0% (placebo), RR 0.33; P<0.001.
- Adverse events and serious adverse events were comparable between groups.
- No COVID-19 related hospitalizations or deaths occurred.
5. Natural killer cell immunotherapy reverses lung fibrosis by eliminating senescent fibroblasts.
Multi-omic and functional studies identify NKG2A as the dominant inhibitory checkpoint on NK cells in fibrotic lungs; senescent fibroblasts express HLA‑E to evade NK clearance. Targeting the HLA‑E–NKG2A axis restores NK antifibrotic activity and reverses fibrosis in preclinical models.
Impact: Defines a mechanistically coherent, druggable checkpoint axis explaining fibrosis persistence and provides proof-of-concept for NK-based antifibrotic immunotherapy.
Clinical Implications: Supports clinical development of NKG2A blockade and NK adoptive strategies with HLA‑E/NKG2A as companion biomarkers for patient selection.
Key Findings
- NKG2A is the predominant inhibitory checkpoint on NK cells in fibrotic lungs.
- Senescent fibroblasts express HLA‑E and suppress NK function via HLA‑E–NKG2A interactions.
- Targeting this axis restores NK antifibrotic activity and reverses fibrosis in preclinical models.